Transforming cancer treatment with Protein Phosphatase 2A inhibitors. Unveiling the first of a novel class of therapeutic agents. $LIXT
BOCA RATON, FL
Joined December 2020
- Tweets117
- Following176
- Followers115
- Likes344
LIXTE Biotech Holdings Inc. (NASDAQ: $LIXT) and Liora Technologies are advancing a multi-modal cancer platform, combining the LiGHT proton therapy system with LB-100 to potentially improve treatment precision and outcomes for patients.
Read more: ibn.fm/8Rcay
LIXTE Biotech Holdings Inc. ( $LIXT ) has appointed Sidney Braun as CEO of Liora Technologies, bringing 20+ years of global healthcare and strategic advisory experience to advance the LiGHT proton therapy platform.
Read more: ibn.fm/BJ7Yy
#BioTech #Healthcare
LIXTE Biotech Holdings Inc. has acquired Liora Technologies, adding the LiGHT proton therapy platform to advance precision cancer care and expand our integrated oncology innovation strategy.
Read more: ibn.fm/HCUrk
#Biotech #CancerResearch $LIXT
We’ve acquired Liora Technologies, bringing the proprietary LiGHT proton therapy system into the LIXTE family. Paired with LB-100, we’re advancing precision radiotherapy + combination cancer care to set a new standard in treatment.
Read more: ibn.fm/Uk4ld
#therapy
Read more about our #LB100 cancer trials in collaboration with GSK and Roche in @PharmaNowGlobal. $LIXT
pharmanow.live/latest-news/l…
Great news … the @LurieCancer of @NorthwesternU has been added as a second site in a clinical trial combining our LB-100 with GSK’s Dostarlimab to treat ovarian clear cell cancer. $LIXT #LB100
ir.lixte.com/news-events/pre…
Click the video link below to learn more about our ovarian cancer trial with @GSK conducted by @MDAndersonNews. $LIXT #LB100 #dostarlimab
vimeo.com/926958077/612466b2…
LIXTE retweeted
René Bernards, Professor of Molecular Carcinogenesis @NKI_nl and member of the #CancerGrandChallenges Scientific Committee, attended our first think tank in Paris.
Read his reflections 👇
In case you missed it, click below to watch a replay of CEO Bas van der Baan present at the Investor Summit Group Summer 2024 Virtual Conference. $LIXT
lnkd.in/giJCVJu3
NEWS ALERT: This morning we announced the dosing of the first patient of a new clinical trial with @NKI_nl and @Roche for treatment of metastatic colorectal cancer. $LIXT #LB100 #cancertreatment
ir.lixte.com/news-events/pre…
Watch our CEO Bas van der Baan present at tomorrow's Summer 2024 Virtual Conference at 2 p.m. EDT. Click below to register. $LIXT
webcaster4.com/Webcast/Page/…
$LIXT will be presenting at two upcoming investor conferences:
The Investor Summit Summer 2024 Virtual Conference on Tuesday, August 20.
The H.C. Wainwright 26th Annual Global Investor Conference September 9-11 .
Register here:
ir.lixte.com/news-events/ir-…
#Lixte #LB100
In this @Clin_Info_News story, Matheus Henrique Dias of the @NKI_nl explains "paradoxical intervention” and how the double stimulation by #LB100 and WEE1 inhibition leads to mitotic disaster and cancer cell death. #Lixte $LIXT #CancerTreatment
clinicalresearchnewsonline.c…
It’s summer ☀️⛱️🕶️🩴but we’ve been busy the past couple of months, from announcing a new chief medical officer to starting a new clinical trial with Roche and the Netherlands Cancer Institute. Click to read recent highlights below. $LIXT #Lixte
ir.lixte.com/news-events/pre…
Data from researchers at @UCSFMedicine, @cityofhope
and the @NKI_nl recently published in @MolOncology demonstrates that PP2A inhibition could enhance the responsiveness of tumors to ICB and other T cell-mediated therapies. #LB100 $LIXT #CancerTreatment
febs.onlinelibrary.wiley.com…
NEW CLINICAL TRIAL: This morning we announced a new clinical trial with @Roche and @NKI_nl to test recent findings that show our #LB100 enhances #immunotherapy in the treatment of colon cancer.
$LIXT #Lixte #CancerTreatment
ir.lixte.com/news-events/pre…
New pre-clinical data from researchers at the @NKI_nl published in @EMBO show that our #LB100 lead molecule can turn immunologically “cold” tumors “hot,” potentially enhancing the benefit #immunotherapy. $LIXT
lnkd.in/gzisTsQP
Click below to watch CEO Bas van der Baan discuss new pre-clinical data that shows how the deliberate hyperactivation of oncogenic signaling combined with our #LB100 can force #cancer cells to give up their cancer-causing properties. ⬇ ⬇ ⬇ ⬇ ⬇ $LIXT
youtu.be/pIWX2mEzjvM?si=Rcm8…
